- Home
- AGIO vs BKV Comparison
AGIO vs BKV Comparison
Compare AGIO & BKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BKV
- Stock Information
- Founded
- AGIO 2007
- BKV 2015
- Country
- AGIO United States
- BKV United States
- Employees
- AGIO N/A
- BKV N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BKV Oil & Gas Production
- Sector
- AGIO Health Care
- BKV Energy
- Exchange
- AGIO Nasdaq
- BKV Nasdaq
- Market Cap
- AGIO 2.4B
- BKV 1.9B
- IPO Year
- AGIO 2013
- BKV 2024
- Fundamental
- Price
- AGIO $41.13
- BKV $23.37
- Analyst Decision
- AGIO Strong Buy
- BKV Buy
- Analyst Count
- AGIO 4
- BKV 7
- Target Price
- AGIO $59.33
- BKV $27.57
- AVG Volume (30 Days)
- AGIO 514.0K
- BKV 471.4K
- Earning Date
- AGIO 10-30-2025
- BKV 11-10-2025
- Dividend Yield
- AGIO N/A
- BKV N/A
- EPS Growth
- AGIO N/A
- BKV N/A
- EPS
- AGIO 11.13
- BKV N/A
- Revenue
- AGIO $40,875,000.00
- BKV $756,795,000.00
- Revenue This Year
- AGIO $23.74
- BKV $48.60
- Revenue Next Year
- AGIO $159.90
- BKV $24.38
- P/E Ratio
- AGIO $3.77
- BKV N/A
- Revenue Growth
- AGIO 30.57
- BKV 13.79
- 52 Week Low
- AGIO $23.42
- BKV $15.00
- 52 Week High
- AGIO $62.58
- BKV $26.78
- Technical
- Relative Strength Index (RSI)
- AGIO 50.11
- BKV 60.52
- Support Level
- AGIO $41.24
- BKV $20.17
- Resistance Level
- AGIO $44.25
- BKV $21.02
- Average True Range (ATR)
- AGIO 1.52
- BKV 0.87
- MACD
- AGIO -0.16
- BKV 0.20
- Stochastic Oscillator
- AGIO 31.28
- BKV 99.58
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BKV BKV Corporation Common Stock
BKV Corp is a growth-driven energy company. Its core business is production of natural gas from its owned and operated upstream businesses. It operates in four business lines: natural gas production, natural gas gathering, processing and transportation (natural gas midstream business), power generation and carbon capture, utilization, and sequestration (CCUS).